Advanced Solid Cancer Trials in China, 2026
Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.
About this register
This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.
This page shows the 10 of those studies listing the condition Advanced Solid Cancer.
How many Advanced Solid Cancer trials are recruiting in China?
6 of the 10 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.
Summary by phase
| Phase | Studies | Recruiting | Share |
|---|---|---|---|
| Phase 1 | 9 | 5 | 90% |
| Phase 1/2 | 1 | 1 | 10% |
Most active sponsors
| Lead sponsor | Studies | Recruiting |
|---|---|---|
| Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | 2 | 1 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | 2 | 2 |
| Ascentage Pharma Group Inc. | 1 | 1 |
| Betta Pharmaceuticals Co., Ltd. | 1 | 0 |
| Minghui Pharmaceutical (Hangzhou) Ltd | 1 | 1 |
| Neowise Biotechnology | 1 | 0 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 1 | 0 |
| TCRx Therapeutics Co.Ltd | 1 | 1 |